1 / 11

ICAS: CTOS 2005 Review of Studies

ICAS: CTOS 2005 Review of Studies. U.S. NCI-funded Intergroup. ICAS: Mission and Vision. NCI-funded coalition of North American cooperative oncology groups with focus in Sarcoma Research

yahto
Télécharger la présentation

ICAS: CTOS 2005 Review of Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ICAS:CTOS 2005 Review of Studies U.S. NCI-funded Intergroup

  2. ICAS: Mission and Vision • NCI-funded coalition of North American cooperative oncology groups with focus in Sarcoma Research • Leverage fixed infrastructures ofSWOG, CALGB, ECOG, and NCI-Canadato advance publicly-funded sarcoma research

  3. What is the Role of ICAS? • Differentiation of work from other smaller groups without NCI funding and with more restricted focus of activities • Where does national and international scale really need to be applied to advance research?

  4. Strengths for Nationally Funded Sarcoma Research Effort • Very large scale effectiveness studies • Casting a very broad net to include the entire continent of physicians and patients • Legitamacy and stability ofpublic sector funding through NCI

  5. Review of ICAS Studies • S0033: randomized GIST testing Imatinib 400 v. 800 • continuing molecular studies • survival long term • other sub-studies in progress

  6. ICAS STUDIESMetastatic Disease ICAS #SarcomaTargetAgent S0330* MPNST EGF-R erlotinib S0345 DFSP PDGF-R imatinib S0346 Synovial HER2 trastuzumab S0505 All STS VEGFR+ sorafenib * First Stage accrual goal reached

  7. ICAS STUDIESMetastatic Disease ICAS #SarcomaTargetInhibitor S0423 Chondro MTAP pemetrexed S0502 GIST KIT/PDGFR Imatinib VEGF bevacizumab S0416 (COG) GIST (Pedi-AYA) KIT/PDGFR imatinib

  8. The Future of ICAS • Choose carefully which trials require full scope of national group mechanism • Optimize efficiency for participation through inclusive investigator registration mechanism • test the function and promise of theClinical Trials Support Unit of NCI)

  9. Z9031 A randomized trial of preoperative radiation plus surgery versus surgery alone for localized primary retroperitoneal STS. P.W.T. Pisters, MD Arm 1:Surgery Patients with primary STS of the retroperitoneum or pelvis R A N D O M I Z E Arm 2:XRT plus Surgery CTSU !!! A C O S O G

  10. Z9001 Phase III randomized double-blind study ofadjuvant Imatinib versus placebo in patientsfollowing resection of primary GIST.Study Coordinator: Ronald DeMatteo, MD Primary GIST > 3 cm Successful Use of CTSU Decentralized Registrations Complete Gross Resection Tumor KIT + Randomize Placebo x 1 yr Imatinib x 1 yr

  11. ACOSOG in Development Phase II evaluation of PET imaging as a predictor of response to neoadjuvant treatment for STS. Edward Cheng, MD (collaborative effort with ACRIN) Neoadjuvant Rx FDG-PET scan, routine staging studies (MRI and CT) Biopsy- Confirmed STS Repeat FDG-PET Wide local excision, histologic assessment of necrosis A C O S O G

More Related